Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$102.72 USD

102.72
7,656,647

-0.24 (-0.23%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $102.67 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

    Boston Scientific Up on Possible Takeover Bid by Stryker

    Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.

      Bio-Rad Banks on Solid Global Scenario, Competition Rife

      Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.

        Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

        Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

          The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

          The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

            Abbott Presents Positive Data for AMPLATZER Amulet Device

            Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

              Abbott Presents Positive Study Results for Tendyne Device

              Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

                Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

                Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

                  Cardiovascular Systems Rides on New Products Amid Tight Race

                  Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.

                    Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

                    Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?

                      Both Merck and Pfizer reported upbeat first-quarter results on May 1

                        Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates

                        Universal Health (UHS) posts a solid Q1 driven by higher revenues.

                          Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance

                          Strong performance across segments supports Anthem's (ANTM) first-quarter results.

                            Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered

                            Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.

                              The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                              The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                                Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

                                Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

                                  MS, USB, ABT & TXT Leads Q1 Earnings

                                  MS, USB, ABT & TXT Leads Q1 Earnings

                                    Mark Vickery headshot

                                    Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT

                                    We are still in the early stages so far, but overall results have been notably better than expected.

                                      Abbott (ABT) Beats on Earnings and Revenues in Q1

                                      Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.

                                        Tracey Ryniec headshot

                                        5 Amazing Earnings Charts This Week

                                        It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.

                                          Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

                                          Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.

                                            Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

                                            Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

                                              Benjamin Rains headshot

                                              3 Stocks to Buy Ahead of Earnings

                                              Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.

                                                Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

                                                Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

                                                  Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

                                                  Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.